Adenosine Derivative for Glaucoma via A3 Receptor Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compounds targeting the adenosine A3 receptor lack selectivity, making it difficult to develop effective therapeutic drugs for conditions like asthma, inflammation, cerebral ischemia, and heart disease, as they often exhibit non-specific activity across different species, hindering clinical development.
Innovation Solution
Development of a pharmaceutical composition comprising an adenosine derivative that acts as a selective adenosine A3 receptor antagonist, specifically designed to inhibit intraocular pressure elevation and glaucoma by inhibiting aqueous humor production and remodeling the trabecular meshwork tissue, using a compound represented by Chemical Formula 1 or its pharmaceutically acceptable salt, which is suitable for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adenosine receptor agonists or antagonists are developed, then pharmacological activity is achieved, but selectivity for specific tissue receptors is lost due to widespread distribution of adenosine receptors throughout the body
Solution Approach 1:
The patent applies local quality by designing adenosine derivatives with specific molecular structures (substituted purine rings with particular R groups at positions 6 and 2) that confer selective affinity for adenosine A3 receptors in ocular tissues. This structural modification enables the compound to preferentially interact with A3 receptors in the eye while having reduced activity at other adenosine receptor subtypes in different tissues, thereby achieving tissue-specific pharmacological effects.
2Object-affected harmful factors
If adenosine derivatives are used to treat glaucoma, then intraocular pressure is lowered, but non-specific activity across different species and tissues hinders clinical development
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of adenosine derivatives, specifically the R groups attached to the purine ring system. By varying these substituent parameters (R1, R2, R3, R4, R5, R6), the invention optimizes the balance between ocular efficacy (lowering intraocular pressure) and selectivity profile, thereby improving clinical development viability through enhanced specificity for ocular A3 receptors.
Data Source
AI summary
A pharmaceutical composition for preventing or treating eye diseases and an oral administration agent for preventing or treating eye diseases are provided, wherein the pharmaceutical composition for preventing or treating eye diseases includes the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.